The opinion of the court was delivered by: Milton I. Shadur Senior United States District Judge
MEMORANDUM OPINION AND ORDER
This pro se action by Jeffrey Paul Sousa ("Sousa") was originally filed in the Circuit Court of Vermilion County, Illinois (Sousa is a prisoner serving time at the Danville Correctional Center, which is located in Vermilion County). AstraZeneca Pharmaceuticals LP ("AstraZeneca," mistakenly named in Sousa's Complaint as "Astra Zeneca Pharmaceutical Inc.") filed a notice of removal ("Notice") to bring the action before the United States District Court for the Central District of Illinois. That court has in turn promptly transferred the action to this District Court for the Northern District of Illinois, and the action has been randomly been assigned to this Court's calendar.
This Court always heeds the admonition stated succinctly nearly a quarter century ago in Wis. Knife Works v. Nat'l Metal Crafters, 781 F.2d 1280, 1282 (7th Cir. 1986):
The first thing a federal judge should do when a complaint is filed is check to see that federal jurisdiction is properly alleged.
Indeed, Wernsing v. Thompson, 423 F.3d 732, 743 (7th Cir. 2005) (internal citations and quotation marks omitted) has more recently mandated:
Jurisdiction is the power to declare law, and without it the federal courts cannot proceed. Accordingly, not only may the federal courts police subject matter jurisdiction sua sponte, they must.
In this instance that threshold scrutiny has disclosed a truly fascinating jurisdictional problem.
In filing the Notice on its own, AstraZeneca has ignored the other defendants whom Sousa expressly targeted in his Complaint. Essentially Sousa's allegations are that when he was in custody at the Cook County Department of Corrections ("County Jail"), he and other inmates were made the subjects of a two-year clinical study involving an AstraZeneca product, the psychotropic medication Seroquel (as Sousa alleges, he was "prodded into" participation in that "select class study").*fn1 Sousa's ingestion of that medication in the course of that study assertedly inflicted an entire battery of dire consequences on him, and so he has sued both AstraZeneca and its on-site employees who administered the study with "a blatant disregard for the health and safety of their former medication user."*fn2
Needless to say, Sousa understandably does not know the identity of those employees, and his obvious lack of mobility as a prison inmate precludes him from learning that identity except through discovery. That being the case, he drafted his case caption by following the AstraZeneca name with "its employees X, Y, Z et al., (unnamed defendants at present)." And that in turn makes it necessary to take a look at the 1988 amendment to 28 U.S.C. §1441,*fn3 part of the chapter of Title 28 dealing with removal, which added the following sentence to Section 1441(a):
For purposes of removal under this chapter, the citizenship of defendants sued under fictitious names shall be disregarded.
As stated in 16 Moore's Federal Practice §107.14[c][iii] at 107-54 to 107-55 (3d ed. 2010), that amendment was adopted to override the en banc decision in Bryant v. Ford Motor Co., 844 F.2d 602 (9th Cir. 1987), which had adopted an across-the-board position that a district court lacked subject matter jurisdiction because of the presence of Doe defendants at the time of a case's removal from the state court. It had been the common practice of lawyers in some states (of which California was the most conspicuous example) to stick one or more "Doe" defendants into a complaint pretty much as a matter of course, whether or not there was a realistic prospect of injecting a real party into the lawsuit at a later date--somewhat in the nature of Dickens' description of Mr. Macawber's favorite expression: "In case anything turned up."
Our own Court of Appeals has spoken instructively on that subject in Howell by Goerdt v. Tribune Entertainment Co., 106 F.3d 215, 218 (7th Cir. 1997):
States often allow a plaintiff to name an unknown party as an additional defendant. E.g., Wis. Stat. §807.12; Carol M. Rice, "Meet John Doe: It Is Time for Federal Civil Procedure to Recognize John Doe Parties," 57 U. Pitt. L. Rev. 883, 892 n. 27 (1996). For that matter, so does federal law in a suit based on the federal question jurisdiction, see, e.g., Bivens v. Six Unknown Named Agents, 403 U.S. 388, 91 S.Ct. 1999, 29 L.Ed.2d 619 (1971), which does not depend on the parties' addresses. But because the existence of diversity jurisdiction cannot be determined without knowledge of every defendant's place of citizenship, "John Doe" defendants are not permitted in federal diversity suits. Moore v. General Motors Pension Plans, 91 F.3d 848, 850 (7th Cir. 1996)(per curiam); United States Fire Ins. Co. v. Charter Financial Group, Inc., 851 F.2d 957, 958 n. 3 (7th Cir. 1988); 14 Charles Alan Wright, Arthur R. Miller & Edward H. Cooper, Federal Practice and Procedure §3642, pp. 144-46 (2d ed. 1985). Indeed, in that last respect the opinion might well have added a reference to this Court's opinion in John Hancock Mut. Life Ins. Co. v. Central Nat'l Bank in Chicago, 555 F.Supp. 1026 (N.D. Ill. 1983), which was one of the earliest cases that rejected a purported diversity action on that basis.
It is more than interesting to note that the cases that allow removal based on the earlier-quoted last sentence of Section 1441(a) quite consistently speak of fictitious defendants, rather than of real defendants about whom everything is known except their names--see, e.g., Australian Gold, Inc. v. Hatfield, 436 F.3d 1228, 1235 (10th Cir. 2006) and Casas Office Machines, Inc. v. Mita Copystar Am., Inc., 42 F.3d 668, 674-75 (1st Cir. 1994); cf. McPhail v. Deere & Co., 529 F.3d 947, 951 ...